Immuron New U.S. Department of Defense Award & Clinical Trial Update

Core Insights - Immuron Limited has entered a new research agreement with the Naval Medical Research Command and the Walter Reed Army Institute of Research, funded by a U.S. Department of Defense subaward, to develop vaccines targeting Campylobacter jejuni and Shigella sonnei [1][2] Company Developments - The collaboration aims to produce two hyper-immune bovine colostrum products for pre-clinical evaluation, specifically designed for the U.S. military [2] - The Uniformed Services University is expected to announce topline results from a clinical trial evaluating the effectiveness of enterotoxigenic E. coli (ETEC) hyperimmune bovine colostrum in maintaining gut health during deployment and travel [3] - Immuron's proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum, allowing for the development of orally active medicines against various infectious diseases [11] Industry Context - Infectious diarrhea is a significant health issue for travelers and U.S. troops, with antibiotic resistance increasing among enteric pathogens [4] - The global burden of diarrheal diseases is substantial, with an estimated 1.5 billion episodes annually, leading to approximately 2.2 million deaths, primarily in children from developing countries [5] - Shigella spp. are responsible for 80-165 million cases of disease worldwide, resulting in 600,000 deaths annually, highlighting the need for preventative treatments [5]